NVCR: Strong Optune Pax launch, robust pipeline, and disciplined execution drive growth outlook
Optune Pax's launch for pancreatic cancer exceeded expectations, with strong patient uptake and early payer coverage, while competitive therapies are not expected to significantly impact momentum. Expansion in Japan and Europe, pipeline progress, and disciplined financial management position the bu…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.